Regenxbio (RGNX) Interest Expenses (2014 - 2025)

Regenxbio's Interest Expenses history runs 12 years deep, the most recent figure standing at -$147.5 million for Q4 2025.

• On a quarterly basis, Interest Expenses fell 1616.32% year-over-year to -$147.5 million in Q4 2025; TTM through Dec 2025 was -$114.8 million, a 709.58% decrease from a year earlier, with the FY2025 full-year figure at $374.4 million, up 10.66% from the prior year.
• Interest Expenses retreated to -$147.5 million in Q4 2025 per RGNX's latest filing, from $13.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $74.1 million in Q3 2021 and bottomed at -$147.5 million in Q4 2025.
• The 5-year median for Interest Expenses is $10.3 million (2023), against an average of $11.4 million.
• Biggest YoY gain for Interest Expenses was 913.0% in 2025; the steepest drop was 1616.32% in 2025.
• Year by year, Interest Expenses stood at $6.5 million in 2021, then sank by 33.69% to $4.3 million in 2022, then jumped by 62.67% to $7.0 million in 2023, then soared by 38.74% to $9.7 million in 2024, then tumbled by 1616.32% to -$147.5 million in 2025.
• Per Business Quant, the three latest RGNX Interest Expenses figures stand at -$147.5 million (Q4 2025), $13.2 million (Q3 2025), and $11.0 million (Q2 2025).